New Longevity Drug for Dogs: What LOY-002 and Rapamycin Trials Actually Mean

I get asked about “the anti-aging pill for dogs” almost weekly now, usually by an owner who read a headline on their phone in my waiting room. The question is never abstract. It’s “will this work for my dog, and is it here yet.” So let’s separate the two things that keep getting mashed together in the coverage: a real drug moving through a real regulatory process, and a much older idea — that a dog’s whole system, not just one organ, ages together — that shapes how I counsel owners in the meantime.

The Pill That’s Closer Than You Think

None of this is theoretical anymore. A company called Loyal has a drug candidate, LOY-002, that has cleared two of the three technical sections the FDA requires for conditional approval. In February 2025, the agency accepted Loyal’s Reasonable Expectation of Effectiveness section — essentially, the FDA agreeing the evidence submitted is plausible enough to proceed — and by January 2026 it had also accepted the Target Animal Safety section. According to Loyal, LOY-002 is designed as a caloric restriction mimetic, meant to deliver some of the metabolic benefits associated with calorie restriction without requiring an owner to actually restrict a senior dog’s food. The company describes the target population as dogs age 10 and older weighing at least 14 pounds. Manufacturing review is the remaining hurdle before Loyal can apply for Expanded Conditional Approval, according to BusinessWire.

Conditional approval is not the same as full approval. It lets a company market a veterinary drug while it continues collecting the effectiveness data required for the full package — a pathway built for exactly this kind of unmet need.

The Other Longevity Bet: Rapamycin and the TRIAD Trial

LOY-002 isn’t the only serious contender. Rapamycin, a drug long used in human transplant medicine, is the subject of the Dog Aging Project’s TRIAD study, which received a five-year, $7 million grant from the National Institute on Aging, per AVMA. The trial is testing a once-weekly, weight-adjusted low dose against a placebo in middle-aged and senior dogs, with a target enrollment of 580 and each dog followed for three years, then monitored for two more. Earlier Dog Aging Project work found improved cardiac function markers at low doses, and researchers have projected — not proven — that rapamycin could add two to five years of healthy life in some dogs. That’s a hypothesis being tested, not a result on the label yet.

I want to be blunt about the distance between “a trial is enrolling” and “a drug is in your dog’s bowl.” Both LOY-002 and rapamycin are years, not months, from a fully approved indication most primary-care vets will prescribe off a shelf.

Where Qi-Balance Thinking Fits While We Wait

In my practice, the dogs I worry about most aren’t the ones already diagnosed with something specific — they’re the ones whose owners can’t quite name what’s changed. I saw a nine-year-old beagle mix, Otis, forty-one pounds, whose owner brought him in not for a limp or a cough but because he’d stopped meeting her at the top of the stairs the way he had every evening for eight years. Nothing on exam or bloodwork jumped out. In TCM terms I’d call that a Qi deficiency pattern — a whole-body dimming rather than one organ failing — and I told her plainly that no supplement or upcoming drug replaces a real workup when something changes. We ran a senior panel, adjusted his joint support, and reassessed in six weeks. The stairs habit came back gradually, over about a month, alongside better energy at his evening walk. I don’t present that as proof of anything; it’s one dog. But it’s why I push owners toward pattern-level thinking before they chase a pill that isn’t approved yet.

That’s my actual position, and I’ll defend it against the obvious counterargument: that meridian and Qi-balance language is unfalsifiable and shouldn’t guide clinical decisions at all. I take that objection seriously — it’s fair, and I don’t use TCM framing to justify a specific dose or override a diagnosis. Where it earns its keep is as a communication tool: it gives owners a way to describe “something is off, broadly” that gets them into the exam room sooner, before it becomes a named diagnosis. Used that way, alongside real bloodwork and imaging, it complements evidence-based medicine instead of substituting for it.

What the Supplement Aisle Can — and Can’t — Promise Right Now

Until a longevity drug actually reaches the pharmacy, most owners are choosing between structure/function supplements built around antioxidants like quercetin and resveratrol. The evidence here is genuinely mixed, and a panel worth trusting says so plainly. A study of quercetin published in Pharmaceuticals found that quercetin formulations, unformulated quercetin, and related antioxidants did not affect feeding behavior in the model organism tested — a narrow, in vitro finding, not a dog outcome, and one that underscores how early this science still is. Resveratrol research is similarly preliminary: a Phytomedicine study found that embryonic exposure to a specific resveratrol concentration accelerated development but shortened adult lifespan in the model tested — a reminder that “more antioxidant” is not automatically “better outcome,” even outside dogs. None of that means these ingredients are worthless; it means the dog-specific longevity data most supplement marketing implies simply isn’t there yet. Our Best Longevity Supplement for Senior Dogs panel review scores products against that reality rather than against the marketing copy, and our Best NAD+ Supplement for Dogs verdict does the same for the NAD+ category specifically. If you’re trying to decide between resveratrol and quercetin for a senior dog’s routine, our Resveratrol vs. Quercetin for Dog Longevity comparison walks through what each ingredient’s evidence actually supports.

The Panel’s Verdict

I had a Labrador mix, Winnie, twelve years old, sixty-eight pounds, come in last spring because she’d started sleeping through the mail truck — a dog who used to bark at it every single day for a decade. Her owner had read about the new drug pipeline online and asked, reasonably, whether she should just wait for LOY-002 rather than “waste money” on anything now. I told her the honest answer: waiting isn’t free. Winnie’s bloodwork showed early kidney changes that benefited from a diet adjustment we could make that week, not in a future approval cycle. We didn’t reach for an unproven longevity pill; we reached for a documented change in her actual body, in front of us, that day.

That’s the verdict I’d hand down for any owner asking about the “new longevity drug for dogs” headlines: track LOY-002 and the rapamycin trial with real interest, because the science is credible and the regulatory movement is real, but don’t let anticipation replace the workup your dog needs now. Structure/function supplements with modest, well-cited evidence — the ones our panel scores highest for dosing and testing transparency — are a reasonable bridge. An unapproved drug is not.